Optoacoustic ultrasound shows potential to reduce false-positives in breast imaging

Optoacoustic ultrasound can help radiologists improve the specificity of breast imaging without leading to a loss in sensitivity, according to a new study published in the American Journal of Roentgenology.

“These criteria are necessary to decrease false-positives, including the percentage of benign biopsies, without increasing false-negatives,” wrote Erin I. Neuschler, MD, department of radiology at the Northwestern University Feinberg School of Medicine in Chicago, and colleagues.

For this prospective study, radiologists used gray-scale ultrasound and optoacoustic imaging to assess 94 breast masses that had already received a BI-RADS score of 3, 4 or 5 from one of seven different facilities.  

Overall, the sensitivity of optoacoustic ultrasound and gray-scale ultrasound was 97.1 percent. Optoacoustic ultrasound had a specificity of 44.3 percent, and internal gray-scale ultrasound had a specificity of 36.4 percent. Optoacoustic ultrasound helped radiologists downgraded more than 41 percent of benign masses or BI-RADS category 3 masses to BI-RADS category 2. In addition, more than 36 percent of BI-RADS category 4A masses were downgraded to BI-RADS category 3 or 2, and more than 10 percent of BI-RADS category 4B masses were downgraded to BI-RADS category 3 or 2.

These statistics suggest optoacoustic ultrasound has potential to significant impact patient care for many patients.

“The number of steps a mass can be downgraded and the final BI-RADS category to which a mass can be downgraded determine the potential effect on patient management,” the authors wrote. “A one-step downgrade of BI-RADS category 4A benign masses to BI-RADS category 3 and a two-step downgrade of BI-RADS category 4B masses to BI-RADS category 3 has the potential to decrease biopsies of benign masses. A one-step downgrade of BI-RADS category 3 masses to BI-RADS category 2 has the potential to decrease the need for short-interval follow-up ultrasound examinations over 2–3 years.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.